Action

JAK1

Alt Name

Approval Jurisdiction

2022 FDA

Approved for clinical use

Atopic dermatitis

Brutto

CAS

1622902-68-4

Commercial Vendor

Pfizer

Compound Image

Abrocitinib.png

Compound name

Abrocitinib

InChI

InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)

InChI Key

IUEWXNHSKRWHDY-UHFFFAOYSA-N

MW

323.42

PubChem CID

78323835

Reference

Reference 2

SMILES

CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3

Approved Drug List

1